Finland suspends use of AstraZeneca vaccines after cases of blood clots
0 Comments

Finland on Friday suspended the use of Oxford-AstraZeneca Covid-19 vaccines after two cases of blood clots were reported in people after receiving the dose

Topics

AstraZeneca | Finland | Coronavirus Vaccine


ANI  | 
Europe 

Finland on Friday suspended the use of Oxford-AstraZeneca COVID-19 vaccines after two cases of blood clots were reported in people after receiving the dose.

This comes despite the European Medicines Agency (EMA) saying that the vaccine is ‘safe and effective’ and the benefits in combating the virus outweigh the risk of side effects.

“According to the Finnish Medicines Agency (Fimea), two cerebral venous thrombosis have been reported in Finland 4-10 days after receiving the AstraZeneca coronavirus vaccine,” said a statement by the Finnish Institute for Health and Welfare (THL), reported Anadolu Agency.

THL suspended vaccination with AstraZeneca jabs as a precaution until further information is available and the existence of a possible causal relationship can be assessed.

The decision will take effect immediately and the situation will be assessed next week, it added, according to the statement.

Anadolu Agency reported that Sweden, Norway, and Denmark will also maintain their suspension of AstraZeneca’s COVID-19 vaccine as they review the European Medicines Agency’s (EMA) conclusion that the jab is safe and effective.

However, vaccination in other countries like Spain, France and more will continue with AstraZeneca COVID-19 vaccines.

The AstraZeneca coronavirus vaccine is “safe and effective” and the benefits in combating COVID-19 continue to outweigh the risk of side effects, said the European Medicines Agency’s (EMA) committee, PRAC, on Thursday after concluding its preliminary review of people vaccinated with COVID-19 vaccine AstraZeneca.

The EMA said that the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it and there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites.

“However, in the light of its findings, patients should be aware of the remote possibility of such syndromes, and if symptoms suggestive of clotting problems occur patients should seek immediate medical attention and inform healthcare professionals of their recent vaccination,” EMA said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Leave a Reply

Your email address will not be published. Required fields are marked *